Dalpiciclib plus fulvestrant and pyrotinib in HR+/HER2-low advanced breast cancer after progression on CDK4/6 inhibition (DapPLE-HER): a Bayesian optimal phase II study
The combination of dalpiciclib, fulvestrant, and pyrotinib demonstrated modest efficacy with a manageable safety profile in HR+/HER2-low advanced BC patients who had progressed on prior CDK4/6i therapy. This novel regimen demonstrated exploratory efficacy and a favorable safety profile, warranting further validation in future randomized controlled studies.
Authors
- Jie Ma (ORCID: https://orcid.org/0000-0003-0451-7923)
- Wenjing Meng (ORCID: https://orcid.org/0000-0002-6329-6430)
- Yuhua Song (ORCID: https://orcid.org/0000-0002-2583-850X)
- Jie Zhang (ORCID: https://orcid.org/0000-0002-2497-725X)
- Yongsheng Jia
- Hua Yang (ORCID: https://orcid.org/0000-0001-7514-7937)
- Jing Shi (ORCID: https://orcid.org/0000-0003-4807-9910)
- Chunfang Hao
- Cuiping Song
Institutions
- Qingdao University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Qinhuangdao Second Hospital (CN)
- Tangshan People's Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Affiliated Hospital of Hebei University (CN)
- China Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1097/js9.0000000000003208
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52